BioSpace News Archive

Adolore Biotherapeutics, Inc. (“Adolore” or the “Company”) today announced the appointments of Roelof Rongen, MSE, MBA as Chief Executive Officer and Director, and Mark C. Rogers, MD, MBA as a member of the Company’s Board of Directors.

Biological Dynamics, Inc., a company developing and commercializing its proprietary ExoVerita™ platform for early disease detection and other applications, today announced Peter C. Wulff as Chief Financial Officer effective January 1, 2023.

Land Science®, a division of REGENESIS®, and the recognized leader in contaminant vapor intrusion mitigation technologies, was recently awarded a U.S. patent for the innovative use of a reinforced geomembrane comprised of an encapsulated, metalized layer and installed with Nitra-Core™, a spray-applied nitrile-modified asphalt.

AXIM Biotechnologies, Inc. (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”) announced today that it has filed a provisional patent application with the U.S. Patent and Trademark Office on an innovative new test designed to measure the neutralizing antibodies against fentanyl, a synthetic opioid responsible for the world’s leading cause of overdose.

Arch Therapeutics, Inc., a marketer and developer of novel self-assembling wound care and biosurgical products, announced that it will effect a 1-for-200 reverse stock split of its outstanding and authorized common stock, effective at 5:00 p.m. on January 17, 2023.

Fulcrum Therapeutics, Inc.®, a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, announced that it has commenced an underwritten public offering of $100.0 million of shares of its common stock.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that new data from its portfolio of blood tests will be presented at the ASCO 2023 Gastrointestinal Cancers Symposium, January 19-21 in San Francisco.

Azura Ophthalmics Ltd. announced that its executive team will hold 1x1 investor meetings during the Private Company Track of the 2023 SVB Securities Global Biopharma Conference being held January 31 through February 2.

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of EZ2 Connect MDx for use in diagnostic laboratories, making the IVD platform for automated sample processing available for widescale use 18 months after being made available for research.

Myomo, Inc. announced the closing of its previously announced “best efforts” public offering of 20,000,000 shares of common stock at a public offering price of $0.325 per share for aggregate gross proceeds of approximately $6.5 million, before deducting placement agent fees and other offering expenses.